Clonidine and Guanfacine for Hyperadrenergic POTS: Turning Down the Sympathetic Signal

The medication that works from the brain, not the heart

Most of the drugs used to calm a racing heart in POTS work at the heart itself. A beta blocker sits on the heart’s adrenergic receptors and blocks adrenaline’s effect there. Ivabradine reaches the pacemaker cells and slows their firing. Clonidine and guanfacine do something different, and for one group of people it is exactly the right thing: they turn down the sympathetic signal at its source, in the brainstem, before it ever reaches the heart or the blood vessels.

That upstream approach is why they are considered specifically for hyperadrenergic POTS, the subtype where the core problem is not blood pooling or low volume but an overactive sympathetic drive. If your POTS feels less like fainting and more like being permanently wired, with a pounding chest, cold and sometimes sweaty hands, tremor, and a sense of adrenaline that will not switch off, this is the mechanism worth understanding.

This is educational field notes, not medical advice, and nothing here is a reason to start, stop, or change a prescription on your own. Clonidine and guanfacine are prescription-only, their use in POTS is off-label, and every dose decision belongs with your clinician. With that said, understanding how they work makes your own tracking far more useful, so let’s walk through the physiology, the difference between the two, the cautions that genuinely matter, and what to watch once one is in the picture.

What is hyperadrenergic POTS?

POTS is not one thing. Clinicians often describe subtypes that overlap: a low-volume type, a neuropathic type with poor blood-vessel constriction and pooling, and a hyperadrenergic type driven by an excess of sympathetic activity. In the hyperadrenergic form, the body leans hard on norepinephrine (also called noradrenaline) to hold blood pressure up on standing, and the result is a state of chronic sympathetic overdrive.

A few features tend to travel with it. Standing often triggers not just a fast heart rate but a genuine rise in blood pressure. Many people describe tremor, anxiety that feels physical rather than emotional, a pounding or fluttering chest, cold extremities, and sometimes flushing or a surge of urine output after being upright. These are the same sensations described in adrenaline dumps, and it is easy to see why hyperadrenergic POTS is so often mistaken for an anxiety disorder: the physical signature is nearly identical because the chemical is the same.

The distinguishing marker clinicians sometimes use is a blood test for standing plasma norepinephrine.

How do clonidine and guanfacine lower the sympathetic signal?

Your sympathetic nervous system is controlled from centers in the brainstem that decide, moment to moment, how much “fight or flight” signal to send out. Those centers carry their own set of brakes: alpha-2 adrenergic receptors that, when stimulated, tell the system to ease off. It is a feedback loop, a way for the body to keep sympathetic output from running away with itself.

Clonidine and guanfacine are central alpha-2 agonists. That means they press on those brake receptors directly. By stimulating the alpha-2 receptors in the brainstem, they reduce the outgoing sympathetic signal, so less norepinephrine is released downstream at the heart and blood vessels. The heart rate falls, the blood pressure falls, and the wired, tremulous quality of hyperadrenergic POTS softens because the chemical driving it is being turned down at the source.

This is the mirror image of a beta blocker. A beta blocker lets the sympathetic signal go out normally and then blocks it at the receptor on the heart. A central alpha-2 agonist reduces the signal upstream, so it never fully arrives. Both end with a slower, calmer heart, but they get there from opposite ends of the same pathway, and the upstream approach also lowers norepinephrine everywhere, not just at the heart.

Clonidine versus guanfacine: how the two differ

Both drugs share the same core mechanism, but their handling in the body differs enough to matter in daily life.

The practical upshot: guanfacine’s longer, steadier action and once-daily dosing often make it the gentler starting point, while clonidine’s transdermal patch can be useful precisely because a steady weekly release avoids the peaks and troughs of pills. Sedation is the trade many people notice first. For some, a small dose at night turns that sedation into an advantage, helping the wired, can’t-switch-off feeling settle enough to sleep. The right choice depends on your blood pressure, how much drowsiness you can absorb, and your clinician’s read on your particular pattern.

Do clonidine and guanfacine actually help POTS?

They can, for the right person, but the honest summary is that the evidence base is thinner than the mechanism is elegant. There is no large randomized trial establishing central alpha-2 agonists as a POTS treatment the way there is for ivabradine in the hyperadrenergic subtype. What exists is clinical experience, small case series, and a place in expert consensus.

The 2015 Heart Rhythm Society expert consensus statement on POTS and related disorders lists central sympatholytics, including clonidine and methyldopa, as options a clinician may consider for patients with a clear hyperadrenergic pattern. Guanfacine has since been used in a similar role, often favored for its gentler profile. The framing in those documents is careful and conditional, which is the right way to hold it: a considered option for a specific subtype, not a first-line drug for POTS in general.

Two caveats keep this in proportion. First, these drugs treat the sympathetic overdrive, not the reason it is there. They do not restore blood volume, reverse deconditioning, or repair an underlying autonomic disturbance. Second, subtype selection is everything. In someone whose main problem is pooling or low volume with a low or borderline blood pressure, lowering blood pressure and sympathetic tone can make standing worse, not better. That is why the same drug that helps one person with POTS can harm another, and why this is a clinician’s decision rather than a pattern to copy from a forum.

What they do to your stand test

The orthostatic stand test is the home measurement most likely to move, and in hyperadrenergic POTS it can move in two useful ways at once. Because the drug lowers heart rate, both your lying and standing rates tend to come down and the jump between them shrinks. And because it lowers norepinephrine, the blood-pressure rise that many hyperadrenergic patients show on standing often softens too.

That second point is the mirror image of the caution. In this subtype, a lower standing blood pressure is usually the goal, because it was running high. In other subtypes it would be a problem. So the stand test is not just tracking whether the drug is working, it is quietly checking that you are the right person for it. Keep taking the test the same way, at the same time relative to your dose, and record both the heart rate and, if you have a cuff, the blood pressure, so you are comparing like with like.

How they change your HRV numbers

If you track heart rate variability, expect your numbers to drift upward on a central alpha-2 agonist, and here the rise is more real than it is with a pure rate drug. Two things push it up together. The obvious one is arithmetic: HRV is measured in milliseconds between beats, so a slower heart rate stretches those intervals and the same relative variability reads as a bigger number. The less obvious one is a genuine autonomic shift. By cutting sympathetic outflow, these drugs move the balance toward the parasympathetic side, which really does raise vagal measures like RMSSD.

That makes clonidine and guanfacine an interesting contrast with ivabradine, which lifts HRV almost entirely through the rate arithmetic because it does not touch autonomic balance. On a central alpha-2 agonist, some of the climb is the nervous system genuinely settling. That is encouraging, but it does not change how you should read it, because the practical rule is the same for any medication that changes heart rate or autonomic tone:

• Treat the dose change as a fresh baseline. Do not compare readings from before and after. You have two separate stories now.
• Measure at a consistent time relative to your dose, so you are not comparing peak effect against a worn-off dose, which matters more with short-acting clonidine than with once-daily guanfacine.
• Watch the multi-week trend on a steady dose, together with your symptom load, rather than reacting to one flattering morning.

The cautions that genuinely matter

Two things about this drug class deserve real attention, beyond the usual list.

The first is rebound hypertension, and it is mostly a clonidine issue. When you take clonidine regularly, your body adapts to the reduced sympathetic tone. If you stop suddenly, the brake comes off all at once and sympathetic activity can rebound above where it started, spiking blood pressure and heart rate, occasionally to a dangerous degree. This is why clonidine is tapered down slowly under supervision rather than stopped on your own, and why missing doses matters more here than with many other medications. Guanfacine’s longer action makes rebound less abrupt, but it is still tapered rather than stopped cold.

The second is sedation and blood pressure. These were designed as blood-pressure drugs, so drowsiness, fatigue, dizziness, and dry mouth are common, especially early on and especially with clonidine. In the hyperadrenergic subtype the blood-pressure lowering is usually wanted, but if you have any orthostatic hypotension mixed in, or your pressure runs low at times, it can tip you into more lightheadedness. Constipation and, less often, low mood can show up too. None of this is a reason to fear the class, and none of it is something you manage alone: your prescriber and pharmacist screen for the cautions, set the dose, and plan the taper.

Frequently asked questions

How do clonidine and guanfacine treat hyperadrenergic POTS? They are central alpha-2 agonists that stimulate the brainstem’s own brake on sympathetic outflow, so the brain sends less “fight or flight” signal to the heart and vessels. That lowers norepinephrine, heart rate, and blood pressure, calming the sympathetic overdrive that defines the hyperadrenergic subtype.

What is the difference between clonidine and guanfacine? Guanfacine is more selective, longer acting, usually once daily, and generally less sedating with a gentler blood-pressure effect. Clonidine is shorter acting, more sedating, available as a weekly patch, and carries a clearer risk of rebound hypertension if stopped suddenly.

Will they lower my blood pressure too much? They can, which is why they are reserved for the hyperadrenergic subtype where standing pressure tends to be normal or high. In someone who already runs low or has orthostatic hypotension, they can worsen lightheadedness.

Do they change HRV readings? Usually your numbers drift up, and the rise is partly real: reduced sympathetic outflow shifts the balance toward the parasympathetic side, and the slower heart rate adds arithmetic on top. Reset your baseline at any dose change and follow the trend.

Why can’t clonidine be stopped suddenly? Because of rebound hypertension. The body adapts to the lowered sympathetic tone, and stopping abruptly can let it surge back above baseline, spiking blood pressure and heart rate. Clonidine is tapered slowly under supervision.

Are they approved for POTS? No. Both are approved for other uses and are prescribed off-label for POTS, based on mechanism and expert consensus rather than a POTS-specific approval. Salt, fluids, compression, and graded exercise remain the foundation.

The bottom line

Clonidine and guanfacine treat POTS from the opposite end of a beta blocker. Instead of blocking adrenaline at the heart, they press on the brainstem’s own brake and reduce how much sympathetic signal leaves the brain at all, lowering norepinephrine, heart rate, and blood pressure together. That upstream action is exactly why they are a considered option for hyperadrenergic POTS, the wired, tremulous, high-norepinephrine subtype, and exactly why they are wrong for someone whose blood pressure already runs low. The evidence is smaller than the mechanism is clean, they are sedating, and clonidine in particular must never be stopped abruptly. If one is in your picture, track your resting heart rate, your stand test, your blood pressure, and how you actually feel, read any HRV rise as partly a genuinely calmer nervous system, and keep every dose decision a conversation with the clinician who prescribes it.